Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis

BioDrugs. 2021 Jul;35(4):469-471. doi: 10.1007/s40259-021-00485-8. Epub 2021 May 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Biosimilar Pharmaceuticals* / adverse effects
  • Etanercept / adverse effects
  • Humans
  • Psoriasis* / drug therapy

Substances

  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • GP2015
  • Etanercept